What Are Next-Generation GLP-1 Cardiometabolic Meds?

“Eli Lilly has one investigational medication in trials and another available by prescription.”

Retatrutide is a triple-hormone receptor agonist and orforglipron is a small-molecule, non-peptide weight management drug that does not break down acids in the stomach without strict fasting or water rules. Both drugs were developed by Eli Lilly and Company to help reduce appetite and manage blood glucose levels during daily food intake. Since retatrutide has not yet been approved by the FDA, there is no commercial consumer product for public use at this time.

Whereas the small-molecule GLP-1 orforglipron was approved by the FDA for chronic weight management in April of this year, it is currently available via a doctor’s exam as a prescription for the brand name Foundayo. However, retatrutide is presently an investigational next-generation receptor agonist in late-stage Phase e clinical trials. Eli Lilly has invested $3.5 billion to manufacture retatrutide and other incretin mimetics upon FDA-approval.

Orforglipron is the first non-peptide small molecule GLP-1 receptor agonist that has received FDA-approval for treating weight loss in obese and overweight patients with certain weight-related metabolic disorders. Because it is not a peptide, acid in the stomach does not break it down and it is readily available for absorption as an anytime of day oral tablet with no strict fasting or water rules. Both orforglipron and retatrutide act exclusively on a single receptor to curb appetite and stabilize blood glucose levels.

Next-Generation GLP-1 Weight Loss Medications - FAQs

How does retatrutide differ from semaglutide or tirzepatide?

Retatrutide is a triple-hormone agonist, activating GLP-1, GIP, and glucagon receptors simultaneously. By contrast, semaglutide targets GLP-1 only, and tirzepatide targets both GLP-1 and GIP. Retatrutide's additional glucagon activation promotes fat mobilization, potentially increasing its weight loss efficacy beyond existing options.

What's different about the daily pill orforglipron?

Specifically, orforglipron is a small-molecule daily pill, semaglutide is a single-action GLP-1 peptide, and tirzepatide is a dual GLP-1/GIP receptor agonist. But, its chemical structure, how many hormone receptors it targets, and how you take it differ. Because it is not a peptide, stomach acid does not break it down, allowing it to be reliably absorbed as a daily oral tablet without strict fasting or water rules.

Is retatrutide and orforglipron safe for people with diabetes?

Retatrutide may increase hypoglycemia risk in people already using insulin or other diabetes medications. If considering participation in a retatrutide clinical trial, individuals with diabetes should consult their physician about adjusting their current prescriptions before enrolling. Orforglipron appears generally safe and effective for managing blood sugar and weight in early trials for type 2 diabetes, showing a safety profile similar to other GLP-1 receptor agonists.

When will retatrutide or orforglipron be available by prescription?

As of 2026, retatrutide is not yet FDA-approved and is only accessible through registered clinical trials. FDA approval timelines depend on the outcome of ongoing Phase 3 trials and subsequent regulatory review. Prospective patients should follow updates from Eli Lilly or consult a specialist for the most current information. Under the brand name Foundayo, orforglipron received FDA approval for chronic weight management on April 1, 2026, and is available.

How effective was retatrutide in clinical trials?

Retatrutide has been exceptionally effective for weight management in clinical trials with Phase 3 results outperforming existing single-action receptor agonists (semaglutide) and dual-hormone incretin mimetic (tirzepatide). In high-dose (12mg) treatment with retatrutide yielded an average of 70-plus pounds of weight loss (28.3% to 30.3% of body weight) at 80 weeks. By subpopulations, adults with type 2 diabetes lost up to 20.8% of body weight and those with obesity and cardiovascular disease up to 22.6% reduction. These results exceeded trial averages for semaglutide and tirzepatide.

How effective was orforglipron in clinical trials?

Orforglipron shows strong effectiveness during clinical trials by reducing blood sugar and lowering body weight. In fact, orforglipron significantly lowered A1C levels compared to placebo, dapagliflozin, and oral semaglutide. At the highest doses observed (36 mg), participant’s A1C had dropped by an average of 1.9% to 2.2% in one year. High doses of orforglipron reduced body weight substantially, averaging roughly 9% to 12% (or more) depending on trial length.

What were orforglipron health benefits during recent trials?

In double-blind randomized Phase 3 trials, the oral non-peptide GLP-1 receptor agonist significantly improved key cardiometabolic markers, such as systolic blood pressure, lipid levels for LDL and triglycerides, and glycemic control. Meaningful reductions in blood pressure were observed in both groups with significant improvement in lipid profiles for cholesterol readings. Inflammatory biomarkers indicated lowering of systemic inflammation for those taking orforglipron. The oral receptor agonist improved all cardiometabolic risk factors measured, including reductions in waist circumference.

What benefits were noticed during retatrutide's investigational trials?

Retatrutide delivered major weight loss alongside improvements in A1C reduction and glycemic control improved significantly (up to 1.6%) in participants with type 2 diabetes. The 12mg dose of retatrutide achieved up to 20.8% to 22.6% weight loss over 80 weeks in adults with obesity, type 2 diabetes, or cardiovascular disease. In fact, cardiometabolic markers showed a decrease in systolic/diastolic blood pressure and waist circumference reduction with mostly dose-related side effects. Unique to retatrutide, trials have also shown positive outcomes for knee osteoarthritis pain and liver-fat reductions for steatotic liver disease.

_______________________

Clinical studies show orforglipron delivered major health improvements that were like injectable GLP-1 single-action and dual-hormone receptor agonists. This daily pill is the first non-peptide oral medication that can be taken once a day without the strict fasting or timing restrictions associated with most oral medications. Marketed as Foundayo, it was FDA approved in April specifically for chronic weight management, but it is not yet approved for treating type 2 diabetes. Although not yet approved by the FDA for use, retatrutide is the leading-edge triple-hormone (GLP-1, GIP and Glucagon) receptor agonist with impressive trial results. At Metabolic Research Center Panama City, our goal is to provide the GLP-1 support needed to create a customized program that preserves crucial muscle mass, limits the common side effects of using a GLP-1 receptor agonist, and produces the changes your body needs for sustainable weight control.